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Integrated whole transcriptome 
and small RNA analysis revealed 
multiple regulatory networks 
in colorectal cancer
Hibah Shaath1,2, Salman M. Toor1, Mohamed Abu Nada3, Eyad Elkord4 & Nehad M. Alajez1,2*
Colorectal cancer (CRC) remains a global disease burden and a leading cause of cancer related deaths 
worldwide. The identification of aberrantly expressed messenger RNA (mRNA), long non-coding RNA 
(lncRNA), and microRNA (miRNA), and the resulting molecular interactions and signaling networks is 
essential for better understanding of CRC, identification of novel diagnostic biomarkers and potential 
development of therapeutic interventions. Herein, we performed microRNA (miRNA) sequencing on 
fifteen CRC and their non-tumor adjacent tissues and whole transcriptome RNA-Seq on six paired 
samples from the same cohort and identified alterations in miRNA, mRNA, and lncRNA expression. 
Computational analyses using Ingenuity Pathway Analysis (IPA) identified multiple activated signaling 
networks in CRC, including ERBB2, RABL6, FOXM1, and NFKB networks, while functional annotation 
highlighted activation of cell proliferation and migration as the hallmark of CRC. IPA in combination 
with in silico prediction algorithms and experimentally validated databases gave insight into the 
complex associations and interactions between downregulated miRNAs and upregulated mRNAs in 
CRC and vice versa. Additionally, potential interaction between differentially expressed lncRNAs such 
as H19, SNHG5, and GATA2-AS1 with multiple miRNAs has been revealed. Taken together, our data 
provides thorough analysis of dysregulated protein-coding and non-coding RNAs in CRC highlighting 
numerous associations and regulatory networks thus providing better understanding of CRC.
CRC is one of the most prevalent types of cancer  worldwide1,2, with an estimated 9% and 8% of all diagnosed 
cancers in males and females respectively, to be attributed to CRC in the United  States1. Better understanding 
of CRC biology and the development of new strategies and therapies targeting CRC is crucial, as the current 
traditional options remain limited to chemotherapy, radiotherapy and surgery, which can be highly invasive, 
involving the use of highly toxic drugs with many undesirable side  effects3,4. In recent years, scientists are realizing 
the importance of post-transcriptional regulation and their effects on cellular processes, and in particular, the 
roles they play in cancer onset and progression. Studying the changes in expression levels of mRNAs, miRNAs, 
and lncRNAs has become of major importance, as well as understanding the effects of their aberrant expression 
patterns on downstream effectors and alterations in important regulatory pathways.
Multiple molecular alterations and genetic signatures have been associated with the onset and progression 
of CRC, which can serve as potential prognostic and predictive biomarkers for the identification of high-risk 
patients. Of the most common gene signatures associated with CRC is the mutation of Adenomatous polyposis coli 
(APC) gene. The encoded tumor suppressor, in addition to preventing uncontrolled growth of cancerous tumors, 
regulates beta-catenin, affecting its interactions with E-cadherin responsible for cell  adhesion5. Apc-mutant cells 
were recently found to be enriched for transcripts encoding several secreted WNT antagonists such as notum. The 
inhibition of NOTUM in Apc-mutant cells prevented their expansion and ability to form intestinal adenomas, 
therefore identifying notum expression as a key mediator in early mutation fixation in CRC 6.
MiRNAs are a large and diverse class of non-coding RNAs, around 18–24 nucleotides in length that are 
known to play a role in cell proliferation, migration and invasion, and have been suggested as potential strategy 
to overcome CRC chemo-resistance in vitro and in experimental  animals7,8. Abnormal expression patterns of 
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miRNAs, detected through microarrays, and more recently, next-generation sequencing, have been implicated 
in a number of human cancers including breast  cancer9,10, cervical squamous cell  carcinoma11, bladder  cancer12, 
and  melanoma13. We previously reported miRNA-320, downregulated in primary CRC, to suppress CRC by 
targeting SOX4, FOXM1, and FOXQ1. Upon lentiviral mediated re-expression of miR-320, growth and migra-
tion of CRC cells in vitro was inhibited, sensitizing them to 5-Fluorouracil (5-FU) therapy, and inhibited tumor 
formation in SCID  mice14.
MiRNAs in cancer seldom work alone, and extensive research has provided us with known associations 
with lncRNAs, another group of non-coding RNAs of around 200  nucleotides15, working independently or 
together as part of an axis in governing specific cellular processes in  cancer16. As an example, a recent study by 
Li et al., demonstrates the suppression of CRC cell growth upon knockdown of lncRNA XIST, via regulating 
microRNA-338-3p/PAX5 axis. This observation may serve as a potential target for the prevention and treatment 
of CRC 16. XIST has also been described, in an earlier study, to inhibit 5-FU -induced cell cytotoxicity through 
promoting thymidylate synthase expression, suggesting the silencing of XIST to be beneficial in overcoming 
chemo-resistance during of CRC  therapy17.
Our previous genome-wide mRNA and miRNA expression profiling revealed multiple regulatory networks 
in CRC including Wnt (wingless-type MMTV integration site family member), matrix metalloproteinase, and 
TGF-β pathways. Pharmacological inhibition of these pathways led to dose- and time-dependent inhibition 
of CRC cell  growth18. In another study, we revealed a number of systemic alterations in gene expression in 
circulation (peripheral blood mononuclear cells (PBMCs)), compared to the tumor microenvironment of CRC 
patients, which revealed activation of immune cell trafficking and cellular movement, and suppression of cellular 
processes related to cell  death19.
In current study, we performed total RNA-seq and miRNA-Seq on paired CRC and adjacent normal tissue. 
Computational analyses identified a myriad of affected mRNA, miRNA and lncRNA interactions in CRC, result-
ing in multiple affected signaling networks. Functional annotation analysis also highlighted activation of cell 
proliferation and migration as the hallmarks of CRC. More in depth understanding of the roles played by the 
identified miRNAs and lncRNAs in CRC is crucial in the identification of potential biomarkers.
Results
Alterations in mRNA expression in CRC compared to NT. CRC tissue and their adjacent NT from 
six patients were subjected to total RNA sequencing. Patients’ characteristics and information on tumor site are 
shown in Table 1. Differential analysis identified several upregulated and downregulated mRNAs in CRC com-
pared to NT (supplementary table 1). Hierarchical clustering of CRC and NT based on differentially expressed 
(log2) mRNAs between the two groups is illustrated in Fig. 1a. The heat map depicts remarkable differences in 
the expression levels of several mRNAs (each row representing an mRNA), grouped in relation to their indicated 
biological processes. Functions related to prostate gland morphogenesis, L-serine biosynthetic process, cytoki-
nesis, chromosomes segregation, and several other cell cycle processes were significantly upregulated (red) in 
CRC tissue compared to NT, as seen in Fig. 1a. Downregulated functions in CRC tissue compared to NT include 
inorganic anion transport, lipid glycosylation, steroid metabolic processes and carbonate dehydratase activity 
(blue). Alterations in mRNA expression between CRC and NT are presented as volcano plot (Fig. 1b), highlight-
ing upregulated mRNAs (red dots) based on log2 FC including PSAT1, DUSP4, CLDN2, S100P, MMP3 and 
MMP1, among several others. Downregulated mRNAs are presented as blue dots on the volcano plot which 
include CA1, CD177, TMIGD1, ZG16, GUCA2A, CLCA1 and CLCA4. Figure  1c,d show the top 5 upregu-
lated mRNAs (MMP3, CLDN2, S100P, KRT17 and CST1) and top five downregulated mRNAs (CLCA1, CA1, 
Table 1.  Characteristic features of study populations. All patients presented with moderately differentiated 
tumors. CRC colorectal cancer.
Patient no. Age (years) Gender TNM stage Tumor location RNA-Seq miRNA-Seq
1 62 Male I Rectosigmoid No Yes
2 47 Male III Ascending colon No Yes
3 65 Female IV Sigmoid colon No Yes
4 65 Male II Cecum No Yes
5 65 Male III Transverse colon No Yes
6 67 Male III Descending colon No Yes
7 96 Male II Sigmoid colon Yes Yes
8 59 Female IV Ascending colon Yes Yes
9 60 Male II Rectosigmoid No Yes
10 75 Male III Rectosigmoid Yes Yes
11 65 Male I Ascending colon Yes Yes
12 52 Male II Transverse colon Yes Yes
13 69 Male I Rectosigmoid No Yes
14 60 Female I Cecum No Yes
15 67 Female IV Ascending colon Yes Yes
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SLC26A3, GUCA2A and ZG16) in CRC vs NT based on RNA-Seq analysis (log2 TPM). The top differentially 
expressed genes identified in our study were compared against the TCGA colon adenocarcinoma (COAD) data-
set. Expression of the top 20 differentially expressed mRNAs in our cohort (10 upregulated and 10 downregu-
lated) in the TCGA COAD dataset is shown in supplementary Fig. 1, revealing high concordance with our data.
Multiple affected signaling network in CRC compared to NT. Differentially expressed mRNAs were 
subsequently subjected to IPA analysis revealing multiple affected signaling networks in CRC compared to NT 
(Fig. 2a). Those upstream regulators most activated with highest Z scores were ERBB2, RABL6, MITF, KDM1A, 
FOXM1, NFkB complex, ERF3, ESR1 AREG, and STAT3. Suppressed upstream regulators with negative Z scores 
were IgG, OGA, TP53, EHMT1, TRPS1, Rb, SP1, EFNA, RC3H1 and CDKN1A. Figure 2b–e show the ERBB2, 
RABL6, FOXM1, and NFkb complex networks in more detail. ERBB2 is predicted to activate RB1, which in 
turn activates E2f. ERBB2’s activation of CHEK1, along with its inhibition of AR, simultaneously inhibit TP53 
(Fig. 2b). The activation of RABL6 is also predicted to have an inhibitory effect on TP53, with both molecules 
also inhibiting RB1. The inhibition of TP53 however, leads to TP63, MYBL2 and FOX01 activation, with RB1 
and TP63 both activating E2f as a third level downstream effect of RABl6 activation (Fig. 2c). FOXM1 activation 
is predicted to lead to the inhibition of the CDKN1A network, which inhibits Rb but activates NFkB complex 
(inconsistent) (Fig. 2d). CDKN1A also inhibits TP53, which has its own downstream consequences as seen in 
Figure 1.  Alteration in mRNA expression in CRC compared to NT. (a) Hierarchical clustering of CRC (n = 6) 
and adjacent normal tissue (n = 6) based on differentially expressed mRNAs between the two groups. Each 
column represents one sample and each row represents an mRNA. Expression level of each mRNA (log2) in a 
single sample is depicted according to the color scale. (b) Volcano plot representation altered mRNAs in CRC vs. 
NT. Red and blue colors indicate the genes with significant increased or decreased expression (− 2.0 ≥ FC ≥ 2.0, 
p < 0.05), respectively, while black color indicates genes with no significant change. Expression of top five 
upregulated (c) or downregulated (d) mRNAs in CRC vs NT based on RNA-Seq analysis.
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Fig. 2c. Figure 2e highlights the downstream effects of NFkB activation, which activates TNF, which in turn 
activates Ap1 but suppresses RELA (inconsistent). This inhibition of RELA is predicted to activate HIF1A as an 
indirect effect of NFkb activation.
Functional category annotation analysis highlights activation of cell proliferation and migra-
tion as the hallmark of CRC . Functional category annotation of differentially expressed mRNAs brought 
forward disease and functions predicted to be altered in CRC. Activated disease and functional categories 
with higher Z scores include tumor cell proliferation, invasion, movement, and cell cycle progression. Those 
suppressed disease functions include transport of ions, cell death of T lymphocytes, non-hematologic malig-
nant neoplasm, secretion of hormones, binding of T lymphocytes and cell death of cancer cells (Fig. 3a). Fig-
ure 3b and c show heat maps illustrating affected downstream biological processes including cellular growth 
and proliferation, and cell death and survival, respectively. Orange boxes depict activation function whereas 
blue highlights suppressed functions. As expected in cancer cells, functional categories associated with cellular 
Figure 2.  Multiple affected signaling networks in CRC. (a) Top altered upstream regulator networks in 
CRC compared to NT based on IPA analysis. Y-axis indicated the upstream regulator network and the x-axis 
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growth and proliferation, colony formation and expansion are activated whereas those associated with cell death, 
apoptosis, and necrosis are suppressed, characteristic of cancer cell persistence.
Alterations in lncRNA expression in CRC compared to NT. LncRNA transcripts were also analyzed 
in the same cohort of six CRC and matched NT revealing several differentially expressed lncRNA transcripts 
(supplementary table  2). Hierarchical clustering of CRC (n = 6) and adjacent NT (n = 6) based on differen-
tially expressed lncRNA transcripts (log2) is shown in Fig.  4a. Upregulated transcripts in CRC tissues (red) 
include LINC01605-202, FIRRE-210, AC124067.2–203, LINC0219-201, LINC01605-201, AL355312.4–201, 
CYTOR-201, MIR4435-2HG-203, GATA2-AS1-201, SNHG5-255, MUC12-AS1-201, MUC12-AS1-202, ZFAS1-
201, AL136131.3–201 and H19-203, while several other lncRNAs were downregulated (Fig. 4a). Figure 4b is a 
volcano plot displaying significantly altered lncRNA transcripts in CRC vs. NT. Blue dots represent the most 
significantly downregulated lncRNA transcripts whereas the red dots depict the most significantly upregulated 
lncRNA transcripts in CRC vs. NT. Figure 4c and d show the expression of top five upregulated (AL136131.3–
201, AL355312.4–201, LINC01605-201, ZFAS1-201 and SNHG5-255) and downregulated (CDKN2B-AS1-220, 
AC025580.1–201, LINC01687-202, AL392086.3–208 and AC073050.1–201) lncRNAs in CRC compared to NT. 
In agreement with our data, several of the top upregulated and downregulated lncRNAs from our study showed 
similar expression pattern in the TCGA COAD dataset (supplementary Fig. 2).
Alterations in miRNA expression in CRC compared to NT. To provide a more comprehensive view 
of alterations in noncoding RNA transcriptome in CRC, miRNA expression profiling was conducted on 15 
CRC tissues compared to the corresponding normal adjacent tissue using miRNA-Seq. Differential expression 
analysis revealed several differentially expressed miRNAs in CRC compared to NT (supplementary table  3). 
Hierarchical clustering based on miRNA expression revealed close clustering of CRC away from NT, except for 
few samples (Fig. 5a). Principle Component Analysis (PCA), showing the degree of relatedness of the samples 
to each other based on PC1 and PC2, also highlighted the clear segregation of the two groups (NT in red and 
CRC in blue), with a slight overlap of a few samples as evident in the hierarchical clustering analysis (Fig. 5b). 
Hsa-miR-133a-3p, hsa-miR-363-3p, hsa-miR-145-5p, hsa-miR-363-3p, and hsa-miR-195-3p, were among the 
downregulated while hsa-miR-135b-5p, hsa-miR-552-5p, hsa-miR-224-5p, hsa-miR-183-5p and hsa-miR-552-3p 
were among those upregulated in CRC. We subsequently validated top 10 upregulated and top 10 downregu-
lated miRNAs from our study in the TCGA COAD dataset which showed high degree of concordance except for 
hsa-miR-138-5p, hsa-miR-1-3p, and hsa-miR-9-5p which were not concordant (supplementary Fig. 3). When 
Figure 3.  Functional category annotation analysis highlights activation of cell proliferation and migration 
as the hallmark of CRC. (a) Disease and function analysis of differentially expressed mRNAs in CRC. Y-axis 
indicated the functional category and the x-axis represent the activation Z score. Heatmap representation of 
cellular growth and proliferation (b) and cell death and survival (c) functional categories. Activation Z score is 
depicted according to the color scale.
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patients were grouped according to disease stage (stage III/IV vs. stage I/II), several miRNAs were found to cor-
relate with disease stage as depicted in Fig. 5c. Among those, hsa-miR-501-3p, hsa-miR-421, hsa-miR-18a-5p, 
hsa-miR-128-3p, hsa-miR-7-5p, and hsa-miR-744-3p, were downregulated while hsa-miR-let-7b-5p, hsa-miR-
30a-5p, hsa-miR-145-5p, hsa-miR-1179, hsa-miR-133a-3p, hsa-miR-504-5p, and hsa-miR-218-5p were upregu-
lated in stage III/IV compared to stage I/II. Figure 5d shows the expression of three upregulated (hsa-miR-4454, 
hsa-miR-122-5p, and hsa-miR-4662a-5p) and three downregulated (hsa-miR-18a-5p, hsa-miR-676-3p, and hsa-
miR-7-5p) miRNAs in CRC stage III/IV compared to stage I/II.
miRNA–mRNA–lncRNA computational interaction prediction. We subsequently integrated the 
miRNA and mRNA expression data using the microRNA filter with IPA thus connecting expression data from 
the current study with in silico prediction and the IPA manually curated database which identified many regula-
tory networks (supplementary table 4). We subsequently focused on the differentially expressed miRNAs and 
Figure 4.  Alteration in lncRNA expression in CRC vs. NT. (a) Hierarchical clustering of CRC (n = 6) and 
adjacent normal tissue (n = 6) based on differentially expressed lncRNA transcripts between the two groups. 
Each column represents one sample and each row represents single lncRNA transcript. Expression levels of 
each transcript (log2) in a single sample is depicted according to the color scale. (b) Volcano plot representation 
of significantly altered lncRNA transcripts in CRC vs. NT. Red and blue colors indicate the transcripts with 
increased or decreased expression, respectively. Black color indicates no significant change. Expression of the 
top five upregulated (c) or downregulated (d) lncRNA transcripts in CRC vs. NT based on RNA-Seq analysis.
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mRNAs in CRC and those which were experimentally observed or predicted with high confidence based on IPA 
analysis which led to the identification of 33 downregulated and 14 upregulated miRNAs and their respected 
mRNA targets. Visualization of the miRNA-mRNA interactions are depicted using cystoscope (Fig. 6). Starting 
with hsa-miR-1-3p, the downregulation of this miRNA is predicted to upregulate IQGAP3, SERPINB5, ORC6 
(also associated with the downregulation of hsa-miR-136-5p), and UHRF1. UHRF1, along with NME4, MYC, 
HMGA1, RRM2, and PRSS22, interact with the downregulated hsa-miR-7c-5p and so on. Figure 6a illustrates in 
detail, the complex associations and interactions between downregulated miRNAs and upregulated mRNAs in 
CRC, including several experimentally validated interactions and associations with high confidence according 
to IPA predictions. Figure 6b shows interactions between upregulated miRNAs and downregulated mRNAs in 
Figure 5.  Alteration in miRNA expression in CRC vs. NT. (a) Hierarchical clustering of CRC (n = 15) and 
adjacent normal tissue (n = 15) based on differentially expressed miRNAs between the two groups. Each column 
represents one sample and each row represents a miRNA. Expression level of each miRNA (log2) in a single 
sample is depicted according to the color scale. (b) PCA analysis depicting relatedness of the samples based 
on PC1 and PC2. (c) Heat map illustrating the most differentially expressed miRNAs in CRC in Stage I/II vs. 
Stage III/IV. Expression level in each sample is depicted according to the color scale. (d) Expression of three 
upregulated (hsa-miR-4454, hsa-miR-122-5p, and hsa-miR-4662a-5p) and three downregulated (hsa-miR-
18a-5p, hsa-miR-676-3p, and hsa-miR-7-5p) in CRC stage III/IV vs. stage I/III.
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Figure 6.  Networks illustrating the interactions between differentially expressed miRNAs and mRNAs in CRC. 
(a) Network illustrating the interaction between downregulated miRNAs and upregulated mRNAs in CRC 
based on Targetscan prediction and IPA analysis. (b) Network illustrating the interaction between upregulated 
miRNAs and downregulated mRNAs in CRC based on Targetscan prediction and IPA analysis. Only 
experimentally validated and interactions with high confidence are included in both networks.
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CRC. For example, upregulated hsa-miR-1268a could downregulate FRRS1, IGLL5, HAVCR1, PYY and PADI2, 
whereas upregulated hsa-miR-1356-5p is predicted to downregulate NR3C2, TMEM236, MB and UGT2B15. 
Other mRNAs can be downregulated by more than one miRNA, such as in the case of SDCBP2, which is down-
regulated by the upregulation of both hsa-miR-503-5p and hsa-miR-549a-3p.
LncRNAs are believed to act as sponge to sequester mature miRNAs and to exert their biological function. 
Therefore, we explored the DIANA-LncBase database connecting differentially expressed lncRNAs and their 
corresponding downregulated miRNAs from the current study. For example, Fig. 7a highlights the complex inter-
actions between miRNAs and lncRNAs in CRC in more detail, illustrating the complex associations predicted in 
CRC. LncRNA H19 is shown to interact with more than 20 downregulated miRNAs including, hsa-miR-378a-3p, 
hsa-miR-30c-2-3p, hsa-miR-22-3p, and hsa-miR-125a-5p. Other miRNAs that interact with H19, also interact 
with other lncRNAs such as hsa-miR-138-5p, which interacts with H19, SNHG5 and GATA2-AS1. Inversely, 
interactions between upregulated miRNAs and downregulated lncRNAs in CRC based on DIANA-LncBase 
database show hsa-miR-503-5p to interact with FAM30A, hsa-miR-17-5p to interact with SATB2-AS1, and hsa-
miR-18a-5p to interact with both LINC02362 and CDKN2B-AS1, which in turn, interacts with all of hsa-miR-
15b-3p, hsa-miR-130b-30, and hsa-miR-183-5p. LncRNA AC009404.1 also shows association with upregulated 
miRNA hsa-miR-183-5p, in addition to both hsa-miR-182-5p and hsa-miR-335-5p (Fig. 7b).
Discussion
Colorectal cancer remains one of the most commonly diagnosed cancers worldwide, and a leading cause of cancer 
related deaths, posing an international burden which is anticipated to worsen according to future  predictions20. 
With this knowledge, studies into alternative methods of identifying susceptibility, early diagnosis and treatment 
is imperative to those affected by CRC. Exploring new avenues through widening our knowledge on the roles 
played by non-coding RNAs, including miRNA and lncRNA in CRC etiology and progression provides great 
prospects in improving survival rates of CRC patients. We performed RNA-Seq and computation analyses to 
characterize the altered mRNA, miRNA and lncRNA expression in CRC compared to NT, as well as identifying 
the affected signaling networks and predicting the interaction between differentially expressed miRNAs and 
mRNAs, and miRNAs and lncRNAs in CRC.
The most upregulated mRNAs in CRC according to our cohort includes MMP3, CLDN2, S100P, and KRT17. 
In a recent study on colon adenocarcinoma (COAD), the most common type of CRC, Zeng and colleagues 
looked into transcriptome data from the TCGA COAD dataset and identified MMP3, in addition to several 
other genes, as prognostic factors for patients with  COAD21 with functional studies showing improved viability 
of colon cancer cell lines and decreased apoptosis  rate22. Other studies have also implicated MMP3 in resistance 
mechanisms, where expression levels of MMP3, MMP9 and MMP14, as well as some cytokines was increased 
in drug‐resistant CRC 23.
Much evidence has also shown the role played by claudin-2 (CLDN2) in breast and CRC 24–27. Claudins 
are a family of proteins making up the most important components of tight junctions. Whereas one study 
shows the upregulation of CLDN1 and CLDN2 in CRC, other CLDNs such as CLDN5, 7, 8, and 23 were down-
regulated, indicating a wide range of roles played by these proteins in CRC. Others such as CLDN11, CLDN12, 
and CLDN23 were associated with longer overall  survival27. The expression of KRT17 transcript and KRT17 
protein as a marker were also significantly associated with poor relapse-free survival (RFS) in stage II CRC 
28,29. Nonetheless, our data highlighted a central role for TP53 in CRC 30. Signaling networks affected by these 
alternations in mRNA in CRC include ERBB2, RABL6, FOXM1, and NFKB networks, some of which we have 
previously reported in  breast31,32 and CRC 19,32.
Aside from protein coding RNA transcripts, our data unraveled multiple dysregulated lncRNAs in CRC. 
Upregulated lncRNA LINC01605 in our data, otherwise known as LincDUSP, has been found to regulate cell cycle 
genes to resist apoptosis in a study by Forrest et al., where the knockdown of lincDUSP in colon tumor cell lines 
increased the accumulation of cells in early S-phase, indicating increased DNA damage response  induction33. 
In a different study, over 80% of CRC samples showed upregulated expression of LINC01605. Depletion of 
LINC01605 led to suppression of proliferation, migration and invasion ability of CRC cells in vitro. Furthermore, 
our data identified LINC01605 to be involved in the miR-3960/SOX11 regulatory axis, which was confirmed 
experimentally by Hu et al.,34. H19 was the most upregulated lncRNA in CRC in our study. Upregulated H19 
correlated with poor prognosis and induces epithelial-to-mesenchymal transition (EMT) in CRC. The knock 
down of hnRNPA2B1, directly bound to H19, attenuated CRC cells ability to migrate and  invade35. Furthermore, 
single-nucleotide polymorphisms (SNPs) identified in the promoter region of H19 significantly increased the risk 
of CRC 36. H19 lncRNA also acts as a sponge for other miRNAs such as miR-22-3P involved in reduced HDAC2 
expression, which strongly promoted CRC lung  metastasis37. Multiple studies highlight a role for ZFAS1 in CRC 
tumorigenesis, where ZFAS1 silencing reduced CRC cell line migration and invasion ability through miR-34b 
direct interaction with ZFAS1 3’ untranslated region (3’UTR)38. The ZFAS1/DDX21/POLR1B signaling regulation 
axis may also be a new biomarker for targeted CRC treatment, where ZFAS1 knockdown dramatically reduced 
cancer cell properties and increase apoptosis. This inhibitory effect could be reversed by DDX21  overexpression39. 
Expanding future studies to include the effects of snoRNAs in CRC is also relevant. LncRNA ZFAS1 activities 
extend to rRNA 2’-O-methylation (Me) in CRC initiation and development through oncogenic upregulation of 
NOP58 and SNORD12C/78 expression in CRC 37.
Other lncRNAs highlighted in this study are novel transcripts with limited annotations including 
AL355312.4–201, simply referred to as antisense to LRP11. Such lncRNAs provide us with further opportunities 
to data mine for future studies; exploring their biological roles in CRC as well as their associations and interac-
tions with other mRNAs and miRNAs.
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Figure 7.  Networks illustrating the interactions between differentially expressed miRNAs and lncRNAs in 
CRC. (a) Network illustrating the interaction between downregulated miRNAs and upregulated lncRNAs in 
CRC based on DIANA-LncBase v3. 0. (b) Network illustrating the interaction between upregulated miRNAs 
and downregulated lncRNAs in CRC based on DIANA-LncBase v3. 0.
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A recent study shows the lncRNA MCF2L-AS1 to provoke proliferation, invasion and glycolysis of CRC via 
the crosstalk with miR-874-3p/FOXM1 signaling  axis40, highlighting the importance of altered interactions 
between mRNAs, miRNAs and lncRNAs in CRC. In addition to this, lncRNA SNHG16 was found to promote 
CRC cell proliferation, migration, and epithelial-mesenchymal transition through miR-124-3p/MCP-141. Our 
data identified several novel lncRNA transcripts including one of the most significantly upregulated, SNHG5, 
while SNHG16 was found to be part of a regulatory circuit involving miR-124-3p, we found SNHG5 to interact 
with miR-132-3p (Fig. 7a), which has previously been reported to affect cell proliferation, metastasis and migra-
tion of CRC through regulating interaction with  CREB542. We identified a number of other different interac-
tions of SNHG5 with miRNAs including hsa-let-7c-5p, hsa-miR-363-3p, hsa-miR-125b-2-3p, hsa-miR-214-3p, 
hsa-miR-9–5-p, hsa-miR-132-3p, hsa-miR-29c-3p, and hsa-miR-10a-5p, amongst others, while other groups have 
also reported on the significance of SNHG5 in CRC 42. Elevated expression of the downregulated miR-let-7c in 
CRC was found to be associated with higher disease control rate (DCR) in metastatic CRC patients treated with 
anti-EGFR  mAbs43,44. The upregulation of miR-let-7c via the silencing of Lin28 in another study, promoting 
apoptosis in CRC cells, indicating the Lin28/let-7c axis as a potential route for novel therapeutic target in CRC 
45. Let-7c is reported to also function as a metastasis suppressor by targeting MMP11 and PBX3 in CRC, with 
its downregulation being significantly associated with metastases, advanced TNM stages and poor survival of 
CRC  patients46. Our data also records the significant downregulation of lncRNA CDKN2B-AS1, which was also 
found to be aberrantly expressed and is suggested as an optimal diagnostic lncRNA biomarker for COAD by 
Huang et al.,47. CDKN2B-AS1 has also been confirmed to be downregulated in another study on CRC staging 
and  progression48.
Emerging data, including our study, have served to solidify the imperative role played by mRNAs, miRNAs, 
and lncRNAs, and their resulting interactions within networks and axes as a result of their aberrant expression 
in CRC. While we have highlighted several aberrantly expressed transcripts described in literature, we have also 
identified multiple novel transcripts and have therefore identified a number of interactions that warrant further 
investigation, which could serve as potential biomarkers, giving us a clearer picture on how mRNA and ncRNA 
play a role in the etiology CRC.
Materials and methods
Ethics statement. All patients included in the study were treatment-naïve and provided a written informed 
consent prior to sample collection. Tumor tissues (TT) and adjacent normal tissues (NT) taken away from tumor 
margins, were cut from freshly resected tissues by pathologists. The study was performed under ethics com-
mittee approvals from Hamad Medical Corporation, Doha, Qatar (Protocol no. MRC-02–18-012) and Qatar 
Biomedical Research Institute, Doha, Qatar (Protocol no. 2017–006). The characteristics of patients included in 
this study are provided in Table 1. All experiments were performed in accordance with the ethical principles of 
the Declaration of Helsinki.
Sample preparation, RNA extraction, and small RNA library preparation. Colorectal cancer tis-
sue and their non-tumor adjacent tissue specimens were cut into small pieces then snap-frozen and were stored 
in liquid nitrogen for use in subsequent experiments. Tissues were homogenized using Tissue Homogenization 
Set from Bioneer Corporation (Daejeon, South Korea) according to manufacturer instructions. Homogenized 
issue lysates were used to extract RNA using the miRNeasy Mini Kit- QIAGEN (Hilden, Germany) according 
to manufacturer instructions. In brief, tissue were lysed and kept at room temperature (15–25 °C) for 5 min, 
chloroform is added, shaking vigorously at room temperature for additional 2–3 min. Samples were centrifuged 
for 15 min at 12,000×g at 4 °C. The aqueous phase was washed with 100% ethanol and added into an RNeasy 
Mini column in a 2 ml collection tube. RWT and RPE buffers are added, then finally RNA is eluted in water in 
a fresh tube. The concentration and purity of extracted RNA were measured using NanoDrop 2000c (Thermo 
Scientific, Waltham, MS, USA). The quantity and quality of extracted RNA was checked using the Agilent RNA 
6000 Nano Kit (Agilent Technologies, Santa Clara, CA, USA) and the Agilent 2100 Bioanalyzer (Agilent Tech-
nologies, USA) as per the manufacturer’s instructions. Samples with RNA Integrity Number (RIN) > 9 were used 
for subsequent analyses.
TruSeq stranded total RNA library preparation. The TruSeq Stranded Total RNA Library Prep Gold 
kit (Cat #: 20020598) from Illumina was used for total RNA library preparation following the manufacturer’s 
protocol. Briefly, 100 ng of total RNA extracted from TT and NT samples was subjected to rRNA depletion and 
then to fragmentation. The first-strand cDNA synthesis was performed with random hexamers and SuperScript 
II Reverse Transcriptase (Cat#: 18064014) from ThermoFisher Scientific. The second cDNA strand synthesis 
was performed by substitution of dTTP with dUTP. The double-stranded cDNA is then end-repaired and ade-
nylated. Barcoded DNA adapters were ligated to both ends of the double-stranded cDNA and then amplified. 
The libraries quality was checked on an Agilent 2100 Bioanalyzer system and quantified using Qubit 2.0 fluo-
rometer (Invitrogen).
QIAseq small RNA (miRNA) library preparation. For small RNA library preparation, 100 ng of RNA 
was subjected to 3’ ligation followed by 5’ ligation and reverse transcription. The next steps included QIAseq 
miRNA NGS (QMN) bead preparation, cDNA cleanup, and finally library amplification using tube indices, 
QIAseq miRNA NGS 96 Index IL kit (QIAGEN, Hilden, Germany). The yield of cDNA libraries was quantified 
using Qubit dsDNA HS assay kit (Invitrogen) and size distribution of the cDNA libraries were determined using 
the Agilent 2100 Bioanalyzer DNA1000 chip (Agilent Technologies). Libraries were subsequently pooled and 
were subjected to illumine sequencing at QBRI genomic core.
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Illumina sequencing and bioinformatics analyses. TruSeq Stranded Total RNA libraries were pooled, 
clustered on a cBot platform, and sequenced on an Illumina HiSeq 4000 at a minimum of 50 million paired 
end reads (2 × 75 bp) per sample. Similarly, miRNA libraries were pooled and were sequenced using the same 
platform (5 million reads per sample). Data were subsequently demultiplexed using illumina suggested pro-
tocols and the resulting FASTQ files were used for further analysis. For total RNA-Seq analysis, FASTQ files 
were subsequently pseudo aligned to the Gencode Release 33 index (mRNA and lncRNA) and reads were sub-
sequently counted using KALLISTO 0.42.1 as previously  described10,19,49. Normalized Transcripts Per Million 
(TPM) expression values were subsequently subjected to differential expression analysis using 2.0-fold change 
and < 0.05 p-value cut-off. Transcripts with raw expression values < 1.0 TPM were excluded from the analysis. 
Hierarchical clustering was performed using cosine for columns and cosine for rows as described  before10,19,50. 
Volcano plots was used to illustrate most differentially expressed genes (log two fold change) vs − log10 p value.
For microRNA analysis, FASTQ files were subjected to small-RNA quantification and differential expression 
analysis in CLC genomics workbench 20.2 using built-in workflow. Initially, raw expression data were mapped 
to the miRbase v22 reference genome. Read counts of mature miRNA were then normalized using the trimmed 
mean of M values (TMM) normalization method. Mature miRNA expression values were then subjected to 
differential analysis as described above. Low abundance miRNAs with expression values < 5.0 count per mil-
lion (CPM) were excluded from the analysis. The microRNA Target Filter in IPA (using the default database) 
was subsequently employed to identify miRNA-mRNA networks based on differentially expressed mRNAs 
and miRNAs from current study. This bioinformatics approach provides insights into the biological effects of 
microRNAs, using corresponding mRNA expression data as well as experimentally validated interactions from 
several databases, and the predicted microRNA-mRNA interactions from TargetScan. Only highly predicted 
and experimentally validated interactions were included in the final analysis. DIANA-LncBase v3 was utilized 
to identify miRNA-lncRNA interactions. Cytoscape 3.8.1 was used to construct miRNA-mRNA and miRNA-
lncRNA networks. Expression values from whole transcriptome RNA-Seq and miRNA-Seq are provided as 
supplementary tables 5 and 6, respectively.
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